142 related articles for article (PubMed ID: 38043937)
1. Successful management of camrelizumab-induced immune-checkpoint-inhibitors-related myocarditis.
Long HD; Du YP; Wang LY; Liu GC; Liang SX; Zeng ZH; Lin YE
J Oncol Pharm Pract; 2024 Apr; 30(3):597-604. PubMed ID: 38043937
[TBL] [Abstract][Full Text] [Related]
2. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review.
Chen Y; Jia Y; Liu Q; Shen Y; Zhu H; Dong X; Huang J; Lu J; Yin Q
Ann Palliat Med; 2021 Jul; 10(7):8512-8517. PubMed ID: 34263614
[TBL] [Abstract][Full Text] [Related]
3. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report.
Delombaerde D; Vervloet D; Berwouts D; Beckers R; Prenen H; Peeters M; Gremonprez F; Croes L; Vulsteke C
J Med Case Rep; 2022 Jul; 16(1):275. PubMed ID: 35831829
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
6. A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.
Guo CW; Alexander M; Dib Y; Lau PKH; Weppler AM; Au-Yeung G; Lee B; Khoo C; Mooney D; Joshi SB; Creati L; Sandhu S
Eur J Cancer; 2020 Jan; 124():15-24. PubMed ID: 31707280
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.
Gao L; Li X; Guo Z; Tang L; Peng J; Liu B
Medicine (Baltimore); 2022 Dec; 101(49):e32240. PubMed ID: 36626474
[TBL] [Abstract][Full Text] [Related]
8. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.
Peleg Hasson S; Salwen B; Sivan A; Shamai S; Geva R; Merimsky O; Raphael A; Shmilovich H; Moshkovits Y; Kapusta L; Rozenbaum Z; Wolf I; Laufer-Perl M
Clin Res Cardiol; 2021 Jan; 110(1):50-60. PubMed ID: 32296970
[TBL] [Abstract][Full Text] [Related]
9. Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy.
Sobol I; Chen CL; Mahmood SS; Borczuk AC
Arch Pathol Lab Med; 2020 Nov; 144(11):1392-1396. PubMed ID: 32150459
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report.
Wang C; Zhong B; He J; Liao X
Medicine (Baltimore); 2023 Apr; 102(15):e33550. PubMed ID: 37058040
[TBL] [Abstract][Full Text] [Related]
11. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
12. Immune-Related Adverse Events Mimicking Behcet's Disease in a Gastric Cancer Patient Following Camrelizumab Treatment.
Wang D; Zhang S; Ding P; Zhao Y; Zhang X; Zhao Q
Iran J Immunol; 2020 Jun; 17(2):167-171. PubMed ID: 32602470
[TBL] [Abstract][Full Text] [Related]
13. Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients.
Ansari-Gilani K; Tirumani SH; Smith DA; Nelson A; Alahmadi A; Hoimes CJ; Ramaiya NH
Emerg Radiol; 2020 Aug; 27(4):455-460. PubMed ID: 32130542
[TBL] [Abstract][Full Text] [Related]
14. A case of Brugada phenocopy alteration induced by immune checkpoint inhibitors.
Zhang J; Jin H
J Electrocardiol; 2023; 81():269-271. PubMed ID: 37924699
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
16. Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels.
Scard C; Nguyen JM; Varey E; Moustaghfir I; Khammari A; Dreno B
Eur J Dermatol; 2021 Apr; 31(2):205-212. PubMed ID: 33814359
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
18. Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature.
Yin B; Xiao J; Wang X; Li X; Guan Y; Chen J; Han P; Li K; Wang J
Front Med (Lausanne); 2022; 9():950801. PubMed ID: 36457566
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.
Wang F; Sun X; Qin S; Hua H; Liu X; Yang L; Yang M
Chin Clin Oncol; 2020 Apr; 9(2):16. PubMed ID: 32279526
[TBL] [Abstract][Full Text] [Related]
20. Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis.
Zhang C; Qin S; Zuo Z
J Oncol Pharm Pract; 2022 Sep; 28(6):1350-1356. PubMed ID: 34192946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]